《波士顿咨询（BCG）：基因编辑将成焦点（英文版）（13页）.pdf》由会员分享，可在线阅读，更多相关《波士顿咨询（BCG）：基因编辑将成焦点（英文版）（13页）.pdf（13页珍藏版）》请在三个皮匠报告上搜索。

1、 2022 Boston Consulting Group1Gene Editing Gets Ready for the SpotlightNOVEMBER 11,2022 By Smruthi Suryaprakash,Souparno Bhattacharya,Wen Xie,and Michael ChoyPharma has invested billions in cell and gene therapies.Gene editing ismaking a case for more of this funding,but companies need to understand

2、what theyre investing in and why.In recent years,pharma has turned significant R&D attention and investment tocell and gene therapiesfor the good reason that these innovations hold thepotential for transformational treatments for patients who were previously beyondthe industrys reach.Reports put pri

3、vate funding at almost$68 billion in 2021.Onecutting-edge technologygene editinghas thus far received only a sliver of this 2022 Boston Consulting Group2funding(which GlobalDatas Pharma Intelligence Center pegs at$1.3 billion in2021),but it looks like thats about to change.CRISPR gets much of the at

4、tentionbut is only one of multiple technologies under development.Investment has beengrowing quickly from its small base,and gene editing has attracted the interest(and investment)of industry leaders such as Pfizer,Roche,and Allergan and haseven received financial backing from tech giant Amazon.The

5、reason is as simple as the technology is complex.While first-generation genetherapies work by adding a gene to the patients cells,gene editing“fixes”thebroken gene itself.This innovation has enormous potential for multipletherapeutic areas,such as oncology,hematology,genetic disorders,and metabolicd

6、iseases.Indeed,the promise of gene editing is such that large pharma companieswhile making major strategic and financial decisions in the broader arena of celland gene therapiesshould also be developing specific plans for gene editing.Here are the factors they need to consider.Big Benefits from Rapi